Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Earnings call transcript: Jubilant Pharmova tops revenue in Q2 2026, shares rise

Earnings call transcript: Jubilant Pharmova tops revenue in Q2 2026, shares rise

Jubilant Pharmova reported a 21% year-over-year rise in quarterly revenue, reaching INR 2,370 crore, with strong growth across its radiopharma, sterile injectables, allergy, and generics businesses. However, profit fell short of expectations due to remediation costs and higher operating expenses. Earnings per share (EPS) came in at 4.6, below the 5.8 expected by analysts, while revenue exceeded forecasts by INR 1.05 billion.

Shares climbed 2.57% to $988.85, indicating investor optimism about the company's outlook for improving margins.

Revenue for the first half of FY 2027 stood at INR 4,599 crore, up 19% year-on-year, with H1 EBITDA at INR 523 crore and profit after tax at INR 87 crore. The Montreal facility, a drag on the company, reported losses of over INR 80 crore in the quarter and cumulative losses of around INR 357 crore since the OAI issues began. Management anticipates margins to improve in the second half of the year, with H2 average EBITDA margins expected in the mid-teens.

The company expects growth in its key businesses, including the RUBY-FILL radiopharma segment and sterile injectables, to be a central part of its long-term strategy. CFO Ashish Mukkirwar reiterated the company's commitment to reducing leverage, with CapEx for FY 2028 projected to fall to about INR 1,000 crore from INR 1,800-1,900 crore in FY 2027, and a Vision 2030 target of zero net debt by the end of FY 2030.

Investors seem to be more focused on the company's revenue growth and management's expectations for improving margins in the near term rather than the EPS miss.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

This story

This is one outlet's version. Read the fullest account.

Every outlet that reported this, and when →

Read the original at investing.com →

More in Finance & Markets

More from Monday 16 November →